| Identification | Back Directory | [Name]
Ethanone, 2-[(3,5-dichlorophenyl)amino]-1-[(3aR,7aR)-octahydro-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6H-pyrrolo[2,3-c]pyridin-6-yl]- | [CAS]
1374240-01-3 | [Synonyms]
BTK-IN-19
Ethanone, 2-[(3,5-dichlorophenyl)amino]-1-[(3aR,7aR)-octahydro-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6H-pyrrolo[2,3-c]pyridin-6-yl]- | [Molecular Formula]
C21H22Cl2N6O | [MOL File]
1374240-01-3.mol | [Molecular Weight]
445.35 |
| Hazard Information | Back Directory | [Uses]
BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC50 of <0.001 μM[1]. | [in vivo]
BTK-IN-19 (Compound 51) (80 mg/kg; i.p.; once) inhibits CD69 in mice[1].
BTK-IN-19 (5 mg/kg; p.o.) demonstrates low-moderate in vivo clearance and modest oral exposure (%F > 34) in rats[1]. | Animal Model: | DBA/1 mice[1] | | Dosage: | 80 mg/kg | | Administration: | IP, once | | Result: | Demonstrated strong inhibition of CD69. |
| [References]
[1] Vandeveer GH, et al. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem Lett. 2022 Dec 17;80:129108. DOI:10.1016/j.bmcl.2022.129108 |
|
|